ESMO 2023: Anticipating Advances in Prostate Cancer Research

Rana R. McKay, MD

October 12, 2023

Rana R. McKay, MD, expects the upcoming ESMO conference in October to deliver a wealth of research, notably the RADICALS-RT trial on post-prostatectomy radiotherapy timing and the AMG 509 phase 1 study in patients with metastatic castration-resistant prostate cancer.

Additionally, attendees can anticipate findings from studies like EMBARK, STAMPEDE subset analyses, and the ARTO trial, along with other new data that will be presented in the abstract sessions.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: ESMO 2023: Anticipating Advances in Prostate Cancer Research - Medscape - Oct 12, 2023.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.